{"entity":{"id":"nct07033598","kind":"trial","name":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","aka":["PROSPERA"],"tldr":"A phase 2 trial of Pacritinib in chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, run by Theradex, now recruiting.","summary":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia is a phase 2 interventional study registered as NCT07033598 by Theradex, with 66 participants planned, started 2026-01-01 and due to reach its primary completion in 2028-07. Interventions recorded: Pacritinib and Hydroxyurea.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07033598","url":"https://clinicaltrials.gov/study/NCT07033598"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cmml"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["pacritinib"],"companies":["sobi"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07033598","phase":"2","setting":"A Randomized Phase 2 Study of Pacritinib vs. Hydroxyurea in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia","sponsor":"Theradex","started":"2026-01-01","startedType":"actual","enrolled":66,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07033598/","neighbours":{"cancer":[{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"pacritinib","kind":"drug","name":"Pacritinib","route":"/drugs/pacritinib/"}],"company":[{"id":"sobi","kind":"company","name":"Sobi (Swedish Orphan Biovitrum)","route":"/companies/sobi/"}]}}